Mark E Sellers
National Institutes of Health · 8 works · 295 citations · h-index 4
Top works
- PRS-02: Gefitinib (IRESSA) versus docetaxel in patients with locally advanced or metastatic non-small-cell lung cancer pre-treated with platinum-based chemotherapy: a randomized, open-label Phase III study (INTEREST)
- Gefitinib or Placebo in Combination with Tamoxifen in Patients with Hormone Receptor–Positive Metastatic Breast Cancer: A Randomized Phase II Study
- 2LB Phase III, randomized, open-label, parallel-group study of oral gefitinib (IRESSA) versus intravenous docetaxel in patients with locally advanced or metastatic non-small-cell lung cancer who have previously received platinum- based chemotherapy (INTEREST)
- The SEER Program’s longstanding commitment to making cancer resources available
- Reply to D. Tassinari et al
- Stat Bite: Recent trends in ovarian cancer among Non-Hispanic Black and Non-Hispanic White women
- Stat Bite: A reversal of esophageal cancer mortality between non-Hispanic Black and White individuals in the United States
- Stat Bite: Cancer risk factors in the US in 2024; obesity, BMI ≥ 30 in people over 20 years